Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
The Central Social Insurance Medical Council (Chuikyo) on March 8 approved a batch of medicines for their reimbursement listing on March 15, with Eli Lilly’s diabetes drug Mounjaro (tirzepatide) boasting the biggest peak sales projection among them, at over 30…
To read the full story
Related Article
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
- Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
- Radicut Oral Form Now Available for ALS Patients in Japan: Mitsubishi Tanabe
April 18, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- Xocova to Be Commercially Available from March 31
March 24, 2023
- Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
March 16, 2023
- AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
March 9, 2023
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
- Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
REGULATORY
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
- MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
March 9, 2026
- Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026
- Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…